Bufalin/Huachansu / COX2 Cancer Research Results

BF, Bufalin/Huachansu: Click to Expand ⟱
Features:
Bufalin/Huachansu is a component from Chinese toad venom. Bufalin is classified as a cardiac glycoside, specifically a type of bufadienolide.

Pathways:
-release of cytochrome c and subsequent activation of caspases
-enhance the expression of death receptors
-inhibit the PI3K/Akt/mTOR
-modulate the MAPK/ERK pathway
-inhibit NF-κB signaling
-induce cell cycle arrest at different checkpoints (commonly G0/G1 or G2/M)
-elevate intracellular ROS levels
-interfere with the Wnt/β-catenin signaling pathway
-modulate autophagy, a process that can either promote cell survival or lead to cell death
-Stabilization or activation of p53

Bufalin — Bufalin is a steroidal cardiotonic toxin and anticancer lead compound, classically isolated from toad venom (ChanSu / Huachansu) and belonging to the bufadienolide subclass of cardiac glycosides. It is commonly abbreviated BF. In cancer research, bufalin is best understood as a pleiotropic signaling disruptor whose most central pharmacology is linked to Na+/K+-ATPase engagement, with downstream effects on survival signaling, mitochondrial death pathways, redox stress, stemness, invasion, and therapy resistance.

Primary mechanisms (ranked):

  1. Na+/K+-ATPase targeting with disruption of pump-linked oncogenic signaling and, in some models, α1-subunit destabilization/degradation.
  2. Mitochondria-linked apoptosis with cytochrome c release, caspase activation, and loss of survival signaling.
  3. Suppression of PI3K/Akt/mTOR and related pro-survival nodes, with context-dependent effects on ERK, NF-κB, and STAT3-linked programs.
  4. ROS elevation with stress-kinase activation (especially JNK/p38) and redox-dependent death signaling; this is important but usually downstream/secondary rather than the first initiating event.
  5. Cell-cycle arrest and mitotic disruption, including Aurora kinase-related effects in some tumor models.
  6. Inhibition of stemness, EMT, migration, invasion, angiogenesis, and drug-resistance phenotypes, including Wnt/β-catenin- and YAP-associated programs in selected cancers.
  7. Autophagy modulation, which can be cytoprotective or cytotoxic depending on model and schedule.

Bioavailability / PK relevance: Translation is constrained by poor water solubility, low/variable bioavailability of bufadienolides, short apparent plasma persistence in human Huachansu infusion studies, and a narrow therapeutic window typical of cardiac glycosides. CYP3A-mediated metabolism and CYP3A4 inhibition/time-dependent inactivation raise drug-interaction concern. Delivery optimization by nanoparticles, prodrugs, and formulation engineering is mechanistically relevant, not merely cosmetic.

In-vitro vs systemic exposure relevance: Concentration-driven. Many mechanistic cancer studies report activity in low-nanomolar to submicromolar ranges, which is closer to plausibility than for many phytochemicals; however, human plasma bufalin levels reported during Huachansu infusion were only low ng/mL and showed little accumulation, so many higher in-vitro conditions likely exceed sustained clinically achieved free exposure. Any interpretation should therefore prioritize low-nanomolar findings and delivery-enabled tumor exposure rather than high-concentration cell-culture effects.

Clinical evidence status: Preclinical to small-human evidence only. There is substantial in-vitro and animal evidence, plus early Huachansu clinical studies in China and a phase I/II development path, but no convincing randomized evidence that bufalin-containing therapy improves major cancer outcomes. Current status is best described as experimental / adjunct-oriented rather than established anticancer therapy.

Mechanistic translation matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Na+/K+-ATPase signalosome ↓ pump-linked oncogenic signaling; ↓ proliferation; apoptosis trigger ↓ ubiquitous pump function; cardiotoxicity risk P-R Upstream target engagement Most central mechanism. Bufalin behaves as a cardiac glycoside/bufadienolide with strong relevance to ATP1A1-linked signaling and tumor vulnerability, but normal-tissue exposure limits selectivity.
2 Mitochondria and intrinsic apoptosis ↑ cytochrome c release; ↑ caspases; ↑ mitochondrial dysfunction ↔ to ↓ tolerance window R-G Cell death induction Robust across many tumor models and commonly downstream of Na+/K+-ATPase disruption, ROS stress, and survival-pathway collapse.
3 PI3K Akt mTOR survival axis ↓ ↔ to ↓ R-G Anti-survival signaling One of the most repeatedly reported downstream axes. Often linked to apoptosis sensitization, growth arrest, and resistance reversal.
4 NF-κB inflammatory survival signaling ↓ ↔ to ↓ R-G Reduced survival and inflammatory tone Usually a secondary convergence node rather than the first molecular hit.
5 Mitochondrial ROS increase ↑ (dose-dependent) ↑ toxicity risk R Stress amplification Mechanistically important in several models, especially where JNK/p38 activation and autophagy-mediated death are observed. Not universal as the dominant initiating event.
6 JNK p38 stress kinase axis ↑ ↔ R-G Pro-apoptotic stress signaling Often coupled to ROS elevation and mitochondrial injury.
7 ERK MAPK signaling ↓ or ↔ (context-dependent) ↔ R-G Growth signaling modulation Reported direction varies by model; best treated as context-dependent rather than universally suppressed.
8 Cell-cycle and mitotic machinery ↑ G0/G1 or G2/M arrest; ↓ Aurora activation ↔ to ↓ proliferative tissues G Cytostasis and mitotic disruption Relevant in multiple cancers; checkpoint phenotype varies by model.
9 Wnt β-catenin stemness axis ↓ stemness; ↓ EMT; ↓ invasion ↔ G Anti-metastatic differentiation pressure Important in selected resistant and stem-like states rather than universally core.
10 Autophagy program ↑ or ↓ (context-dependent) ↔ R-G Death modulator Can either support survival or contribute to death. Interpretation must stay model-specific.
11 Chemosensitization and resistance reversal ↑ sensitivity ↔ G Adjunct potential Preclinical evidence is strong enough to keep this high in translational interest, but human confirmation is still weak.
12 Clinical Translation Constraint Exposure limited Systemic toxicity relevant G Therapeutic window constraint Poor solubility, formulation dependence, short plasma persistence, CYP3A liability, and cardiac-glycoside toxicity remain the main barriers to direct clinical deployment.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
5728- BF,    Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action
- in-vitro, Lung, A549
TumCP↓, Apoptosis↑, TumCCA↑, Bcl-2↝, BAX↝, Cyt‑c↝, Casp3↝, PARP↝, P21↝, cycD1/CCND1↝, COX2↝, p‑VEGFR2↓, EGFR↓, Akt↓, NF-kB↓, p44↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↝, 1,   Bcl-2↝, 1,   Casp3↝, 1,   Cyt‑c↝, 1,  

DNA Damage & Repair ⓘ

PARP↝, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↝, 1,   P21↝, 1,   TumCCA↑, 1,  

Migration ⓘ

p44↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   p‑VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↝, 1,   NF-kB↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:49  Target#:66  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page